Page 219

United States. Their experience is likely to be more predictive of the marketing prospects for other cannabinoids. It is too early to forecast the prospects for cannabinoids, other than to note that their development at this point is considered to be especially risky, to judge by the paucity of products in development and the small size of the pharmaceutical firms sponsoring them.

The market outlook in the United States is distinctly unfavorable for the marijuana plant and for cannabinoids found in the plant. Commercial interest in bringing them to market appears nonexistent. Cannabinoids in the plant are automatically placed in the most restrictive schedule of the Controlled Substances Act, and this is a substantial deterrent to development. Not only is the plant itself subject to the same scheduling strictures as are individual plant cannabinoids, but development of marijuana also is encumbered by a constellation of scientific, regulatory, and commercial impediments to availability.

References

1. Abrahamov A, Abrahamov A, Mechoulam R. 1995. An efficient new cannabinoid antiemetic in pediatric oncology. Life Sciences 56:2097-2102.

2. Abrams DI. 1998. Medical marijuana: Tribulations and trials. Journal of Psyclhoactive Drugs 30:163-169.

3. AMA (American Medical Association Council on Scientific Affairs). 1997. Report to the AMA House of Delegates. Chicago: AMA.

4. Annas GJ. 1997. Reefer madness—the federal response to California's medical-marijuana law. The New England Journal of Medicine 337:435-439.

5. Arno PS, Bonuck K, Davis M. 1995. Rare diseases, drug development, and AIDS: The impact of the Orphan Drug Act. Milbank Quarterly 73:231-252.

6. Asbury C. 1991. The Orphan Drug Act: The first seven years. Journal of the American Medical Association 265:893-897.

7. Atlantic Pharmaceuticals. 1997. Atlantic Pharmaceuticals' proprietary compound shows promising anti-inflammatory effects in pre-clinical trials [WWW document]. URL http://www.atlan.com/p-ll-10-97ct3zurier.htm (accessed September 1998).

8. Beal JE, Olson RLL, Morales JO, Bellman P, Yangco B, Lefkowitz L, Plasse TF, Shepard KV. 1995. Dronabinol as a treatment for anorexia associated with weight loss in patients with AIDS. Journal of Pain and Symptom Management 10:89-97.

9. Beal JE, Olson R, Lefkowitz L, Laubenstein L, Bellman P, Yangco B, Morales JO, Murphy R, Powderly W, Plasse TF, Mosdell KW, Shepard KV. 1997. Long-term efficacy and safety of dronabinol for acquired immunodeficiency syndrome-associated anorexia. Journal of Pain and Symptom Management 14:7-14.

10. Boseley S. 1998. Multiple sclerosis victims to test medicinal effects of marijuana [WWW document].URL http://www.anomalous-images/news/news/227.HTML (accessed September 8, 1998).



The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement